Scholarlink

<p>This study aims to find the best isolate of local yogurts with their probiotic and anticancer properties. Several traditional yogurt samples were collected from mountain regions in the north of Iran and cultured in MRS agar medium. Lactobacilli were identified using morphologic and biochemical tests. In continuation, molecular identification of the best isolated Lactobacillus with probiotic properties was performed and anticancer effect of new isolate was evaluated. Also, analysis of isolate secondary metabolites was performed by GC–MS method and molecular binding of secondary metabolites to target gene products interpreted with complementary docking studies. <i>Limosilactobacillus fermentum</i> IR2022.2 extract (IC<sub>50</sub> of 2.24&#xa0;mg/mL) induced apoptosis and inhibited cell proliferation by modulating the TEN/PI3K/AKT pathway in HT-29 colon cancer cells. After GC–MS analysis the eight metabolites were selected for molecular docking studies 2-Methyl-7-phenylindole, 2-Methyl-5&#xa0;H-dibenz[b, f]azepine, Hexadecane, trans-1-Benzyloxy-2-methoxy-4-(1-propenyl)benzene, Phenol, 2,4bis(1,1dimethylethyl, Eicosane, Tetradecane. Six of those showed anticancer activities. The best metabolite with the most anticancer activity were 2-Methyl-7-phenylindole, 2-Methyl-5&#xa0;H-dibenz[b, f]azepine. Our analysis suggested that these metabolites of a new isolate from traditional Iranian yogurt with anticancer activity greater than the reference strain ATCC14931, can use as a complementary agent in cancer therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High anticancer activity potential of the new strain Limosilactobacillus fermentum isolated from traditional Iranian yogurt on HT-29 colon cancer cells with modulation of the PTEN/PI3K/AKT pathway and complementary docking studies

  • 期刊论文

  • 发表日期：

    2025年8月12日

查看全文
  • Sohrab Ahrabi,
  • Masoumeh Anvari,
  • Babak Rahmani

摘要

This study aims to find the best isolate of local yogurts with their probiotic and anticancer properties. Several traditional yogurt samples were collected from mountain regions in the north of Iran and cultured in MRS agar medium. Lactobacilli were identified using morphologic and biochemical tests. In continuation, molecular identification of the best isolated Lactobacillus with probiotic properties was performed and anticancer effect of new isolate was evaluated. Also, analysis of isolate secondary metabolites was performed by GC–MS method and molecular binding of secondary metabolites to target gene products interpreted with complementary docking studies. Limosilactobacillus fermentum IR2022.2 extract (IC50 of 2.24 mg/mL) induced apoptosis and inhibited cell proliferation by modulating the TEN/PI3K/AKT pathway in HT-29 colon cancer cells. After GC–MS analysis the eight metabolites were selected for molecular docking studies 2-Methyl-7-phenylindole, 2-Methyl-5 H-dibenz[b, f]azepine, Hexadecane, trans-1-Benzyloxy-2-methoxy-4-(1-propenyl)benzene, Phenol, 2,4bis(1,1dimethylethyl, Eicosane, Tetradecane. Six of those showed anticancer activities. The best metabolite with the most anticancer activity were 2-Methyl-7-phenylindole, 2-Methyl-5 H-dibenz[b, f]azepine. Our analysis suggested that these metabolites of a new isolate from traditional Iranian yogurt with anticancer activity greater than the reference strain ATCC14931, can use as a complementary agent in cancer therapeutic strategies.